# Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics

> **NCT00216684** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 139 (actual)

## Conditions studied

- Pain, Intractable

## Interventions

- **DRUG:** fentanyl

## Key facts

- **NCT ID:** NCT00216684
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2011-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216684, "Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00216684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*